Table 3

Characteristics of surgical samples and rebiopsies (n=87)

n (% miss.)No change in PD-L1 score group* (N=55)Change in PD-L1 score group (N=32)P value†
Summary estimateSummary estimate
Female gender87 (0)27 (49%)8 (25%)0.027
Age at diagnosis (years)87 (0)63 (58–68)63 (56–68)0.876
ECOG performance status74 (15)//0.900
 0 points/22 (45%)10 (40%)/
 1 point/23 (47%)14 (56%)/
 ≥2 points/4 (8%)1 (4%)/
Smoking status66 (24)//0.645
 Never/4 (10%)1 (4%)/
 Current or former/38 (90%)23 (96%)/
Histology87 (0)//0.251
 Adenocarcinoma/37 (67%)16 (50%)/
 Squamous cell carcinoma/17 (31%)15 (47%)/
 Other/1 (2%)1 (3%)/
Postoperative tumor stage85 (2)//0.319
 I/8 (15%)9 (28%)/
 II/23 (43%)13 (41%)/
 III/22 (42%)10 (31%)/
Any adjuvant treatment87 (0)17 (31%)12 (38%)0.529
Time between surgery and rebiopsy ≥1 year87 (0)37 (67%)18 (56%)0.304
Site of rebiopsy87 (0)//0.548
 Local recurrence/26 (47%)13 (41%)/
 Distant recurrence/29 (53%)19 (59%)/
  • *PD-L1 score group (PD-L1 negative, PD-L1 low (1%–49%), and PD-L1 high (50%–100%)).

  • †χ2 test.